Login to Your Account

Clinic Roundup

Thursday, March 28, 2013
• Lightlake Therapeutics Inc., of London, said data from a Phase II trial testing opioid antagonist nasal spray for patients with binge eating disorder showed that patients in the intranasal naloxone group showed a statistically significant 75.2 percent reduction in binge eating.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription